| Literature DB >> 30680519 |
Iwona Pawłowska1, Grzegorz Ziółkowski2, Jadwiga Wójkowska-Mach3, Tomasz Bielecki4.
Abstract
OBJECTIVE: The aims of the study were to analyse the surgical site infections (SSIs) in patients operated at an orthopaedic ward and to describe the drug-resistance of the aetiology of those infections. Also, analyse the possibility of SSI control through microbiological surveillance. Additionally, we have studied the information inferred by aggregating cumulative antibiograms for the SSIs of the studied orthopaedic unit.Entities:
Keywords: Cumulative antibiogram; Laboratory-based surveillance; Multidrug-resistant microorganisms; Orthopaedics; Surgical site infections
Year: 2019 PMID: 30680519 PMCID: PMC6698262 DOI: 10.1007/s00264-019-04298-x
Source DB: PubMed Journal: Int Orthop ISSN: 0341-2695 Impact factor: 3.075
Characteristics of the patients operated at the Department and Clinic of Orthopaedic and Trauma Surgery in 2013–2015
| Studied patients | Incidence rate (%) | OR (95%CI) | |||
|---|---|---|---|---|---|
| With SSI | Without SSI | ||||
| Age (year) | |||||
| 0–15 | 4 (1.2) | 172 (3.5) | 0.07 | 0.3 (0.12–0.87) | |
| 16–29 | 59 (17.1) | 784 (16.0) | 1.13 | 1.1 (0.81–1.45) | |
| 30–45 | 76 (22.0) | 1074 (21.9) | 1.45 | 1.0 (0.77–1.31) | |
| 46–59 | 91 (26.4) | 1185 (24.2) | 1.74 | 1.1 (0.87–1.44) | |
| 60–75 | 100 (29.0) | 1287 (26.3) | 1.91 | 1.1 (0.89–1.46) | |
| > 75 | 15 (4.3) | 392 (8.00) | 0.29 | 0.5 (0.31–0.88) | |
| Gender | |||||
| Female | 139 (40.3) | 2097 (42.8) | 2.65 | 0.9 (0.72–1.12) | |
| Male | 206 (59.7) | 2797 (57.2) | 3.93 | ||
OR (95%CI) odds ratio and 95% confidence interval, SSI surgical site infections
Characteristics of patients, operations and SSIs
| Risk factors | HPRO | KPRO | OPRO | OMS | ||||
|---|---|---|---|---|---|---|---|---|
| SSI | SSI | SSI | SSI | |||||
| No | Yes | No | Yes | No | Yes | No | Yes | |
| Duration of operation (min) | ||||||||
| Mean | 140 | 155 | 110 | 120 | 60 | 65 | 120 | 125 |
| SD | 42 | 43 | 36 | 36 | 16 | 16 | 38 | 38 |
| 0.0503 | 0.3123 | 0.1971 | 0.0556 | |||||
| P75 (min) | 160 | 130 | 94 | 135 | ||||
| Age (years) | ||||||||
| Mean | 67.0 | 69.1 | 66.8 | 69.0 | 49.8 | 46.7 | 47.9 | 62.0 |
| SD | 18 | 18 | 18 | 18 | 16 | 16 | 16 | 18 |
| 0.5215 | 0.6564 | 0.4235 | < 00001 | |||||
| The duration of the pre-hospitalisation (days) | ||||||||
| Mean | 6 | 6 | 6 | 6 | 4 | 4 | 3 | 4 |
| SD | 7 | 7 | 7 | 7 | 6 | 6 | 4 | 4 |
| 1.0000 | 1.0000 | 1.0000 | 0.0003 | |||||
| Gender (%) | ||||||||
| Male | 55.3 | 53.1 | 58.1 | 57.1 | 51.5 | 55.6 | 70.6 | 64.5 |
| Female | 44.7 | 46.9 | 41.9 | 42.9 | 48.5 | 44.4 | 29.4 | 35.5 |
| 0.8139 | 0.9413 | 0.7348 | 0.0520 | |||||
| OR (95%CI) | 0.8 (0.57–1.19) | 0.07 (0.04–0.11) | 0.7 (0.5–1.2) | 1.1 (0.9–1.3) | ||||
| Cleanliness of the surgical site (%) | ||||||||
| Clean, clean-contaminated | 99.8 | 100.0 | 99.6 | 100.0 | 99.7 | 100.0 | 93.0 | 82.0 |
| Contaminated, dirty | 0.2 | 0.0 | 0.4 | 0.0 | 0.3 | 0.0 | 7.0 | 18.0 |
| 0.8096 | 0.8155 | 0.8183 | < 0.0001 | |||||
| OR (95%CI) | 1.0 (0.61–1.66) | 1.00 (0.48–2.11) | 1.00 (0.51–1.96) | 0.88 (0.72–1.1) | ||||
| State of the patient in the ASA scale (%) | ||||||||
| 1 or 2 | 67.6 | 53.1 | 69.8 | 42.9 | 76.9 | 72.2 | 83.0 | 86.0 |
| 3 or 4 or 5 | 32.4 | 46.9 | 30.2 | 57.1 | 23.1 | 27.8 | 17.0 | 14.0 |
| 0.0916 | 0.0349 | 0.6474 | 0.2503 | |||||
| OR (95%CI) | 0.8 (0.9–3.8) | 3.0 (1.1–8.9) | 1.3 (0.4–3.7) | 0.8 (0.5–1.2) | ||||
| Incidence rate (%) | 5.8 | 5.4 | 5.3 | 7.7 | ||||
| Clinical form of the SSI, | ||||||||
| Superficial | 16 (50.0) | 12 (85.7) | 15 (83.3) | 97 (42.5) | ||||
| Deep | 14 (43.8) | 2 (14.3) | 3 (16.7) | 125 (54.8) | ||||
| Organ/space | 2 (6.3) | 0 (0.0) | 0 (0.0) | 6 (2.6) | ||||
| Time of detection of SSI, | ||||||||
| During hospital stay | 7 (21.9) | 4 (28.6) | 4 (22.2) | 139 (61.0) | ||||
| Post-disleftge | 12 (37.5) | 7 (50.0) | 14 (77.8) | 49 (21.5) | ||||
| Re-hospitalisation | 13 (40.6) | 3 (21.4) | 0 (0.0) | 40 (17.5) | ||||
ASA the American Society of Anesthesiologists physical status classification, HPRO hip endoarthroplasty, KPRO knee endoarthroplasty, OMS other musculoskeletal, OPRO other prostheses, OR (95%CI) odds ratio and 95% confidence interval, P75 75th percentile of duration of operation, SD standard deviation, SSI surgical site infections
Most frequently isolated aetiological factors of SSIs at the Department and Clinic of Orthopaedic and Trauma Surgery in 2013–2015
| Pathogen | Ranking | MDR*, | Trend of occurrence | |
|---|---|---|---|---|
| Gram-positive | 225 (56.0) | n/a | ||
| Coagulase-negative staphylococci | 81 | 1 | ||
| | 65 (16.1) | 2 | 17 (26.2)** | Tau = 0.3; |
| | 49 | 3 | n/a | |
| | 10 | 9 | ||
| Others | 20 | 8 | ||
| Gram-negative | 175 (43.5) | |||
| | 41 | 4 | 40 (97.6) | Tau = − 0.8; |
| | 30 | 5 | 4 (16.7) | Tau = 0.8; |
| | 22 | 6 | 11 (50.0) | Tau = − 1.0; |
| | 21 | 7 | n/a | |
| | 20 | 8 | 7 (35.0) | Tau = 1.0; |
| | 20 | 8 | 4 (20.0) | Tau = 1.0; |
| Others | 21 | 7 | n/a | |
| 2 | ||||
| Total | 402 (100) | 91 (22.6) | Tau = − 0.3; | |
*Other MDR 8 (3.8%)
**Only MRSA
MDR multidrug-resistant, including extended-spectrum beta-lactamases (ESBL) and methicillin-resistant Staphylococcus aureus (MRSA), n/a not available
The cumulative antibiogram report, prepared in compliance with the Formula for Rational Empiric Antimicrobial Therapy (FRAT)
| Pathogen | % | Amikacin | Ceftazidime | Ciprofloxacin | Imipenem | ||||
|---|---|---|---|---|---|---|---|---|---|
| % | IF | % | IF | % | IF | % | IF | ||
| Coagulase-negative staphylococcus | 20.1 | 6 | 1.2 | n/a | n/a | 24 | 4.8 | n/a | n/a |
|
| 16.2 | 50 | 8.1 | n/a | n/a | 53 | 7.0 | n/a | n/a |
|
| 10.2 | 3 | 0.3 | 0 | 0 | 4 | 0.4 | 17 | 1.7 |
|
| 6.0 | 82 | 4.9 | 71 | 4.3 | 65 | 4.0 | 100 | 6 |
|
| 5.5 | 60 | 3.9 | 38 | 2.1 | 46 | 2.5 | 100 | 5.5 |
|
| 5.2 | 95 | 4.9 | 71 | 3.7 | 87 | 4.5 | 100 | 5.2 |
|
| 5.0 | 67 | 3.4 | 68 | 3.4 | 50 | 2.5 | 29 | 1.5 |
|
| 5.0 | 100 | 5.0 | 89 | 4.5 | 68 | 3.4 | 80 | 4 |
| Percentage of overall activity | 43.3 | 24.6 | 29.8 | 32.7 | |||||
n/a not available; %I percentage frequency of isolation, %S percentage sensitivity of pathogen to antibiotic, IF antimicrobial impact factor: the likelihood that a pathogen would be sensitive to an antimicrobial drug, (%I × %S) ∕ 100